ANIP

Nov 05, 10:42 AMANI beats Q3 2026 estimates, raises 2026 EPS guidance despite Cortrophin cut, agrees $560M Egetis deal for Emcitate

Peers: AMRX AMPH BHC ETON HROW RDY VTRS TEVA COLL EYPT

| Held by: IJR AVUV VTI IWM PJP VXF DFAT IWO SPSM DFAS

Scroll to Statements

Index	RUT
Market Cap	1.56B
Enterprise Value	1.73B
Income	108.53M
Sales	1.04B
Book/sh	27.82
Cash/sh	19.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	970
IPO	May 12, 2000

P/E	13.58
Forward P/E	6.67
PEG	0.51
P/S	1.50
P/B	2.44
P/C	3.58
P/FCF	7.61
EV/EBITDA	7.16
EV/Sales	1.66
Quick Ratio	2.33
Current Ratio	2.75
Debt/Eq	0.95
LT Debt/Eq	0.92
Option/Short	Yes / Yes

EPS (ttm)	5.01
EPS next Y	10.20
EPS next Q	2.61
EPS this Y	19.69%
EPS next Y	8.06%
EPS next 5Y	13.15%
EPS past 3/5Y	- -
Sales past 3/5Y	40.81% 33.48%
EPS Y/Y TTM	743.87%
Sales Y/Y TTM	25.94%
EPS Q/Q	33.23%
Sales Q/Q	27.64%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	23.64% 3.63%

Insider Own	12.13%
Insider Trans	-4.08%
Inst Own	101.82%
Inst Trans	-2.18%
ROA	7.29%
ROE	18.99%
ROIC	8.89%
Gross Margin	53.11%
Oper. Margin	15.32%
Profit Margin	10.42%
SMA20	-5.26%
SMA50	-6.23%
SMA200	-11.99%
Trades

Shs Outstand	22.89M
Shs Float	20.18M
Short Float	17.21%
Short Ratio	8.55
Short Interest	3.47M
52W High	95.45 -28.74%
52W Low	68.79 -1.12%
Volatility	4.36% 3.11%
ATR (14)	2.49
RSI (14)	36.28
Beta	0.48
Rel Volume	0.98
Avg Volume	405.85K
Volume	386,135

Perf Week	-5.53%
Perf Month	-5.51%
Perf Quarter	-10.22%
Perf Half Y	-16.91%
Perf YTD	-13.84%
Perf Year	-24.62%
Perf 3Y	8.05%
Perf 5Y	35.98%
Perf 10Y	35.22%
Recom	1.62
Target Price	103.38
Prev Close	69.62
Price	68.02
Change %	-2.30%

Consensus

Buy

Avg. Price Target

$103.38

Implied Upside

+52.0%

Analysts13incl. previous ratings

Rating Distribution9 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 23, 2026	Initiated	OOppenheimer	Perform
Sep 09, 2026	Initiated	LLeerink Partners	Outperform	$104	+52.9%
Jul 17, 2026	Initiated	CCanaccord Genuity	Hold	$91	+33.8%
Jul 10, 2025	Initiated	HH.C. Wainwright	Buy	$84	+23.5%
Mar 14, 2025	Initiated	JJefferies	Buy	$80	+17.6%
Mar 12, 2025	Initiated	JJP Morgan	Overweight	$85	+25.0%
Dec 11, 2024	Initiated	LLeerink Partners	Outperform	$80	+17.6%
Oct 11, 2024	Initiated	PPiper Sandler	Overweight	$68	0.0%
Mar 15, 2024	Initiated	CCapitalOne	Overweight	$80	+17.6%
Aug 22, 2023	Reiterated	HH.C. Wainwright	Buy	$60 → $73	+7.3%
Mar 01, 2023	Initiated	GGuggenheim	Buy	$55	-19.1%
Sep 07, 2022	Initiated	HH.C. Wainwright	Buy	$50	-26.5%
Nov 02, 2021	Initiated	TTruist	Buy	$70	+2.9%
May 07, 2020	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Sep 12, 2019	Initiated	GGuggenheim	Buy
May 10, 2019	Downgrade	RRaymond James	Strong Buy → Outperform	$73 → $82	+20.6%
Oct 16, 2017	Reiterated	CCanaccord Genuity	Buy	$60 → $66	-3.0%
Jul 31, 2017	Initiated	CCanaccord Genuity	Buy	$60	-11.8%
Feb 22, 2017	Downgrade	RROTH Capital	Buy → Neutral
Jun 23, 2016	Initiated	RRaymond James	Strong Buy	$68	0.0%

Today 08:13AM	Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (BioPharma Dive)
Nov-05-26 10:46AM	ANI Pharmaceuticals Beats On Diversified Strength, But A Second Cortrophin Guidance Cut Overshadows The Egetis Deal (Earnings Whispers)
06:59AM	ANI: Q3 Earnings Snapshot (Associated Press)
06:51AM	ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire)
06:50AM	REPEAT - ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire)
01:33AM	Loading…
01:33AM	ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire)
Nov-03-26 06:55AM	ANI Pharmaceuticals to Present at Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-26 01:05PM	ANI Pharmaceuticals Needs Cortrophin To Hit Its Trimmed Third-Quarter Guide As The Gout Launch Faces Scrutiny (Earnings Whispers)
Oct-23-26 06:55AM	ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET (GlobeNewswire)
Oct-19-26 06:55AM	ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules (GlobeNewswire)
Oct-12-26 06:55AM	ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire)
Sep-30-26 06:55AM	ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire)
Sep-23-26 06:55AM	ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension (GlobeNewswire)
Sep-03-26 06:55AM	ANI Pharmaceuticals to Present at September Investor Conferences (GlobeNewswire)
Aug-24-26 06:55AM	ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors (GlobeNewswire)
03:01PM	Loading…
Aug-07-26 03:01PM	ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -5.30%
09:59AM	ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut (InvestorsHub)
07:02AM	ANI: Q2 Earnings Snapshot (Associated Press)
06:50AM	ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-24-26 06:50AM	ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET (GlobeNewswire)
Jul-16-26 04:34PM	ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter (GlobeNewswire)
Jul-13-26 06:50AM	ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis (GlobeNewswire)
May-27-26 06:50AM	ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-26 03:02AM	ANI Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-26 09:45AM	ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook (InvestorsHub)
06:59AM	ANI: Q1 Earnings Snapshot (Associated Press)
06:50AM	ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance (GlobeNewswire)
Apr-24-26 06:50AM	ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET (GlobeNewswire)
Apr-20-26 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity (GlobeNewswire)
Apr-13-26 06:50AM	ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules (GlobeNewswire)
08:01PM	Loading…
Apr-08-26 08:01PM	Is American Well (AMWL) Outperforming Other Medical Stocks This Year? (Quartz)
06:50AM	ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet (GlobeNewswire)
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
06:50AM	ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology (GlobeNewswire)
Mar-10-26 11:38AM	GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
11:31AM	JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer (Zacks)
11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
09:55AM	BMY Advances CELMoD Program With Positive Phase III Results (Zacks)
Mar-09-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) (Zacks)
12:11PM	INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz (Zacks)
12:02PM	BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis (Zacks)
Mar-06-26 10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 12:43PM	Bayer Advances Roundup Settlement With Missouri Court Approval (Zacks)
12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
08:24AM	AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know (Zacks)
Mar-04-26 10:35PM	Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best (StockStory)
10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
10:34AM	TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study (Zacks)
Mar-03-26 08:42AM	ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. (MarketBeat)
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks)
Feb-27-26 02:01PM	ANI Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Highlights: Record Revenue and Strong ... (GuruFocus.com)
12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks)
12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
10:24AM	ANI Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
09:46AM	ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% (Benzinga)
09:30AM	ANI (ANIP) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:05AM	ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:24AM	ANI Pharmaceuticals Reaffirms FY26 Outlook; Swings To Profit In Q4; Stock Up 7.6% - Update (RTT News)
07:08AM	ANI: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% (StockStory)
06:50AM	ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance (GlobeNewswire)
Feb-26-26 11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-24-26 06:50AM	ANI Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 07:25PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
10:35AM	Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings? (Zacks)
Feb-20-26 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-13-26 06:50AM	ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET (GlobeNewswire)
Feb-12-26 06:00PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-09-26 05:05PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Feb-06-26 09:40AM	Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? (Zacks)
Feb-03-26 09:40AM	Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? (Zacks)
Jan-27-26 08:51AM	Implied Volatility Surging for ANI Pharmaceuticals Stock Options (Zacks)
Jan-20-26 11:30PM	3 Value Stocks with Questionable Fundamentals (StockStory)
Jan-16-26 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:52AM	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? (Zacks)
Jan-15-26 08:32AM	ANIP Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 12:02AM	ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth (MarketBeat)
Jan-13-26 12:01PM	ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why (StockStory)
04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 04:05PM	Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today (StockStory) +10.58%
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
09:57AM	Stocks Retreat on Concerns Over Fed Independence (Barchart)
06:50AM	ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities (GlobeNewswire)
Jan-06-26 04:15PM	ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks)
10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks)
Jan-04-26 11:03PM	3 Reasons to Avoid ANIP and 1 Stock to Buy Instead (StockStory)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAREY STEPHEN P.	SVP & CFO	Oct 29 '26	Sale	72.87	2,850	207,680	166,143	Oct 30 04:36 PM
STEPHEN CAREY	Officer	Oct 29 '26	Proposed Sale	71.71	8,550	613,120		Oct 29 04:20 PM
Lalwani Nikhil	PRESIDENT & CEO	Oct 15 '26	Sale	71.89	5,400	388,206	333,689	Oct 16 06:50 PM
NIKHIL LALWANI	Director	Oct 15 '26	Proposed Sale	70.16	5,400	378,864		Oct 15 04:25 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 13 '26	Sale	73.59	500	36,795	73,424	Oct 13 08:47 PM
CAREY STEPHEN P.	SVP & CFO	Sep 29 '26	Sale	73.00	2,850	208,050	168,993	Sep 30 04:52 PM
Lalwani Nikhil	PRESIDENT & CEO	Sep 15 '26	Sale	71.00	5,400	383,400	339,089	Sep 16 04:20 PM
NIKHIL LALWANI	Director	Sep 15 '26	Proposed Sale	70.40	5,400	380,160		Sep 15 04:24 PM
Thoma Jeanne	Director	Sep 11 '26	Sale	71.53	1,000	71,530	26,762	Sep 14 08:57 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 14 '26	Sale	70.79	500	35,395	73,924	Sep 14 08:56 PM
JEANNE THOMA	Director	Sep 11 '26	Proposed Sale	71.46	1,000	71,460		Sep 11 04:33 PM
CAREY STEPHEN P.	SVP & CFO	Aug 31 '26	Sale	72.80	2,850	207,480	171,843	Sep 01 06:18 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 25 '26	Sale	74.30	5,400	401,220	344,489	Aug 26 06:15 PM
NIKHIL LALWANI	Director	Aug 25 '26	Proposed Sale	74.17	5,400	400,518		Aug 25 04:42 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '26	Sale	75.48	500	37,740	74,424	Aug 13 04:32 PM
Gutwerg Ori	SVP, GENERICS	Aug 10 '26	Sale	77.00	3,162	243,474	75,534	Aug 11 08:57 PM
CAREY STEPHEN P.	SVP & CFO	Jul 29 '26	Sale	81.36	2,850	231,876	174,693	Jul 30 04:02 PM
STEPHEN P CAREY	Officer	Jul 29 '26	Proposed Sale	81.04	6,163	499,450		Jul 29 04:21 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 13 '26	Sale	81.84	500	40,920	77,390	Jul 14 04:02 PM
PATRICK WALSH	Director	Jul 07 '26	Proposed Sale	86.19	4,336	373,720		Jul 07 04:04 PM
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Option Exercise	49.51	3,313	164,027	180,856	Jul 06 09:40 PM
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Sale	86.00	3,313	284,918	177,543	Jul 06 09:40 PM
CAREY STEPHEN P.	SVP & CFO	Jun 29 '26	Sale	84.12	2,850	239,742	177,543	Jun 30 04:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 12 '26	Sale	82.03	500	41,015	77,890	Jun 15 06:44 PM
HAUGHEY THOMAS	Director	Jun 08 '26	Sale	80.88	2,000	161,760	38,878	Jun 10 09:06 PM
CAREY STEPHEN P.	SVP & CFO	Jun 05 '26	Option Exercise	49.51	3,312	163,977	183,705	Jun 09 06:33 PM
CAREY STEPHEN P.	SVP & CFO	Jun 05 '26	Sale	80.00	3,312	264,960	180,393	Jun 09 06:33 PM
THOMAS HAUGHEY	Director	Jun 08 '26	Proposed Sale	81.11	2,000	162,220		Jun 08 04:36 PM
STEPHEN P CAREY	Officer	Jun 05 '26	Proposed Sale	79.20	11,862	939,470		Jun 05 04:48 PM
Walsh Patrick D	Director	May 13 '26	Sale	80.63	10,000	806,300	38,432	May 13 08:22 PM
Walsh Patrick D	Director	May 11 '26	Sale	80.75	3,973	320,820	48,432	May 13 08:22 PM
Rowland Thomas Andrew	SVP, HEAD - ESTABLISHED BRANDS	May 12 '26	Sale	79.21	459	36,357	38,271	May 13 04:16 PM
Lalwani Nikhil	PRESIDENT & CEO	May 11 '26	Sale	77.57	55,000	4,266,350	349,889	May 13 04:16 PM
Gutwerg Ori	SVP, GENERICS	May 12 '26	Sale	79.50	2,772	220,374	78,696	May 13 04:15 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '26	Sale	78.16	500	39,080	78,390	May 13 04:15 PM
Walsh Patrick D	Director	May 13 '26	Proposed Sale	79.56	10,000	795,600		May 13 11:04 AM
NIKHIL LALWANI	Officer	May 11 '26	Proposed Sale	77.57	55,000	4,266,564		May 11 06:34 PM
PATRICK WALSH	Director	May 11 '26	Proposed Sale	80.75	3,973	320,820		May 11 04:51 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 13 '26	Sale	77.95	500	38,975	78,890	Apr 13 04:40 PM
Rowland Thomas Andrew	SVP, HEAD - ESTABLISHED BRANDS	Mar 11 '26	Sale	74.91	4,772	357,471	38,730	Mar 13 05:28 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 13 '26	Sale	71.64	3,162	226,526	91,309	Mar 13 05:28 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '26	Sale	72.62	500	36,310	79,390	Mar 13 05:28 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 09 '26	Sale	74.18	3,602	267,196	94,471	Mar 10 04:09 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 06 '26	Sale	74.22	2,121	157,421	101,387	Mar 10 04:09 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 09 '26	Sale	74.13	5,087	377,099	51,946	Mar 10 04:06 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 06 '26	Sale	75.00	1,485	111,375	57,033	Mar 10 04:06 PM
CAREY STEPHEN P.	SVP & CFO	Mar 05 '26	Option Exercise	49.51	3,312	163,977	192,855	Mar 05 05:46 PM
CAREY STEPHEN P.	SVP & CFO	Mar 05 '26	Sale	75.50	7,312	552,031	185,543	Mar 05 05:46 PM
STEPHEN P CAREY	Officer	Mar 05 '26	Proposed Sale	75.49	7,312	552,017		Mar 05 05:22 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 02 '26	Sale	74.00	417	30,858	103,508	Mar 04 06:46 PM
Gutwerg Ori	SVP, GENERICS	Mar 03 '26	Sale	76.50	2,060	157,590	84,782	Mar 04 06:45 PM
Walsh Patrick D	Director	Mar 03 '26	Sale	74.23	6,000	445,380	52,405	Mar 03 06:01 PM
PATRICK WALSH	Director	Mar 03 '26	Proposed Sale	74.23	6,000	445,390		Mar 03 04:24 PM
Mutz Christopher	HEAD OF RARE DISEASE	Feb 20 '26	Sale	78.02	5,323	415,300	84,840	Feb 23 05:31 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 19 '26	Sale	77.53	2,084	161,573	50,993	Feb 23 05:31 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 20 '26	Sale	77.99	1,730	134,923	49,263	Feb 23 05:31 PM
Mutz Christopher	HEAD OF RARE DISEASE	Feb 12 '26	Sale	76.55	7,032	538,300	92,566	Feb 17 04:08 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '26	Sale	76.80	500	38,400	69,329	Feb 17 04:04 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '26	Sale	84.33	500	42,165	74,374	Jan 14 06:14 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 18 '25	Sale	82.40	1,622	133,653	58,564	Dec 19 04:47 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 12 '25	Sale	82.32	400	32,928	74,874	Dec 12 04:26 PM
TANNENBAUM RENEE P	Director	Dec 05 '25	Sale	81.15	1,800	146,070	25,157	Dec 09 06:09 PM
RENATE PLAWNER TANNENBAUM 2024	Director	Dec 05 '25	Proposed Sale	81.15	1,800	146,070		Dec 09 05:12 PM
Walsh Patrick D	Director	Nov 13 '25	Sale	86.88	8,643	750,904	61,405	Nov 17 06:01 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Nov 12 '25	Sale	89.07	14,642	1,304,163	158,584	Nov 14 04:30 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Nov 13 '25	Sale	88.00	94	8,272	158,490	Nov 14 04:30 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '25	Sale	87.27	400	34,908	75,274	Nov 14 04:26 PM
PATRICK WALSH	Director	Nov 13 '25	Proposed Sale	86.88	8,643	750,914		Nov 13 04:48 PM

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

PresidentMr. Nikhil Lalwani

Senior VP of Finance & CFOMr. Stephen P. Carey

Senior VPMs. Meredith W. Cook J.D.

Senior VP & Head of Rare DiseaseMr. Christopher K. Mutz

Senior Vice President of GenericsMr. Ori Gutwerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANI Pharmaceuticals Inc

Upgrade your Finviz experience